A Single Arm Open-Label Pilot Study to Investigate the Safety and Clinical Activity of Cemiplimab, A Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients With Incurable NUT Carcinoma (NC)

Summary

This phase II trial studies how well cemiplimab works in treating patients with nuclear protein of testis (NUT) carcinoma for which no treatment is currently available (incurable) and that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Description

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Procedure
  Biopsy Procedure

  Undergo optional biopsy

• Procedure
  Biospecimen Collection

  Undergo collection of blood samples

• Biological
  Cemiplimab

  Given IV

• Procedure
  Computed Tomography

  Undergo CT

• Other
  Digital Photography

  Undergo digital photography

• Procedure
  Magnetic Resonance Imaging

  Undergo MRI

• Other
  Questionnaire Administration

Location